Quantcast

Latest Minimed Paradigm Stories

2014-08-26 12:28:35

9 major insurance companies in Canada approved the reimbursement of the Montméd Timesulin under "standard group policies that include coverage for diabetic supplies". MONTREAL, Aug. 26, 2014 When it comes to diabetes supplies, innovations are often accused of having very little clinical relevance. But Timesulin happens to answer a real medical need. Fitting most of insulin disposable pen on the market, Timesulin shows how long it's been since your last injection. One advantage...

2014-08-12 12:28:18

Company's Network and Technology Enable Trial of Artificial Pancreas in California NEW YORK, Aug. 12, 2014 /PRNewswire/ -- Kids and teens with Type 1 diabetes are swimming, rock climbing, hiking and playing various field sports in the redwoods of the Santa Cruz Mountains - all while testing a device that automatically measures their blood sugar and determines how much insulin they'll need. Using Verizon's network technology, campers aged 7 to 17 are participating in a clinical...

2014-08-04 12:34:38

LONDON, Aug. 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: World Glucose Self-Testing Markets http://www.reportbuyer.com/pharma_healthcare/diseases/diabetes/world_glucose_self_testing_markets.html The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition...

2014-07-03 11:56:28

The Lancet Insulin pumps are significantly more effective at controlling blood glucose (sugar) in people with type 2 diabetes who have failed to respond to the usual standard of care, multiple daily insulin injections, according to the largest international study to examine the safety and effectiveness of the pumps to treat type 2 diabetes, published in The Lancet. Type 2 diabetes is usually controlled by diet and medication, but most people with advanced disease also end up needing...

2014-05-22 08:28:42

DUBLIN, May 22, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/wqkgq3/continuous) has announced the addition of the "Global Continuous Glucose Monitoring (Guardian Real Time, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo CGM Systems) Market - Forecast to 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The rapid rise in diabetic population across the globe has considerably...

2014-05-08 08:33:32

ALBANY, New York, May 8, 2014 /PRNewswire/ -- MRRBIZ includes new market research report "Continuous Glucose Monitoring Market (Guardian Real Time, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo CGM Systems And Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its large collection of research report. This report studies the current scenario as well as the future market potential for...

2014-04-15 23:12:19

Avail is conducting a 6-week, Phase 2 randomized study to assess the safety, tolerability and pharmacodynamics of a new combination therapy administered to participants with type 2 diabetes mellitus. DeLand, FL (PRWEB) April 15, 2014 *To see if you qualify for this Diabetes Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance required, and you may receive...

2014-04-02 04:21:16

DUBLIN, April 2, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/ch672j/continuous) has announced the addition of the "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Global Forecasts to 2020" [http://www.researchandmarkets.com/research/ch672j/continuous ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Continuous...

2014-03-31 08:29:38

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex(® )recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin...

2014-03-19 08:28:16

ALBANY, New York, March 19, 2014 /PRNewswire/ -- MarketResearchReports.Biz includes new market research report "Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" to its large collection of research report. http://www.marketresearchreports.biz/analysis-details/continuous-glucose-monitoring-cgm-market-global-industry-analysis-size-share-growth-trends-and-forecast-2012-2018 This report studies the...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related